Results 121 to 130 of about 19,663 (194)

Analyzing resistance pattern of non-small cell lung cancer to crizotinib using molecular dynamic approaches

, 2015
23-28Crizotinib is the potential anticancer drug used for the treatment of non-small cell lung cancer (NSCLC) approved by FDA in 2011. The main target for the crizotinib is anaplastic lymphoma kinase (ALK).
Kumar, Anish, Ramanathan, K
core  

Targeting Oncogenic Gene Fusions in Lung Cancer. [PDF]

Cancer J
Nie Y, Wilson FH.
europepmc   +1 more source

Clinical Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors for the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer Based on the 2nd Edition of China's Drug Evaluation and Selection Guideline. [PDF]

Drug Des Devel Ther
Guo Z, Zhang Y, Chen H, Dong X, Lei W, Zhong L, Yang J, Huang H, Chen Z, Liang W.   +9 more
europepmc   +1 more source

Three decades of anaplastic lymphoma kinase: from physiological roles to cancer and immune evasion. [PDF]

Cancer Metastasis Rev
Amin HM, Aminnia S, Saber MM, Kannan MK, Hung J.   +4 more
europepmc   +1 more source

Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK. [PDF]

Lung Cancer Manag
Le H, Ladino D, Lowry C, Rifi N, Baijal S.   +4 more
europepmc   +1 more source

CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas. [PDF]

Leukemia
Babin L, Andraos E, Fuchs S, Bessière C, Colras L, Dailhau S, Quelen C, Pinto C, Daoudi I, Pfeifer R, Zamani A, Bousquet M, Pyronnet S, Gaspin C, Lamant L, Meggetto F.   +15 more
europepmc   +1 more source

Case Report: Tyrosine kinase inhibitors in ROS1-rearranged and granulocyte colony-stimulating factor-producing lung squamous cell carcinoma. [PDF]

Front Oncol
Li R, Zhang S, Liu Z, Wu X.
europepmc   +1 more source

Inflammatory Myofibroblastic Tumor of the Central Airways: Case Report and Review of Diagnostic and Therapeutic Strategies. [PDF]

Case Rep Pulmonol
Ehab A, Benabdallah N, Yasin I, Klein U, Büscher E, Borkhardt A, Darwiche K.   +6 more
europepmc   +1 more source

Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare <i>WDR43::ALK</i> structural deletion. [PDF]

Front Oncol
Epler L, Velasquez G, Mambetsariev I, Arias-Romero J, Fricke J, Chen N, Babikian R, Ngo L, Arvanitis L, Kulkarni AA, Urgun DA, Gruber S, Afkhami M, Salgia R.   +13 more
europepmc   +1 more source

Development and Validation of a UPLC-MS/MS Method for Simultaneous Quantification of Ensartinib and Its Major Metabolite M465 in Rat Plasma and Application to Pharmacokinetic Studies. [PDF]

Drug Des Devel Ther
Jiang S, Chen Y, Cao L, Fu H, Wang P, Yang C.   +5 more
europepmc   +1 more source